ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CTNM / options
EBS (48) CAPR (34) SPRY (20) GALT (37) ⌘ Pro Terminal β†’

Contineum Therapeutics Inc. (Class A) (CTNM) Options Positioning, Max Pain & Unusual Sweeps

$9.56 +1.81% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.57

Contineum Therapeutics Inc. (Class A) (CTNM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $353.3M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CTNM Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CTNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Contineum Therapeutics Inc. (Class A) (NASDAQ: CTNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $9.56 (+1.81% 1D, market cap $353.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTNM ranks #858 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CTNM compare to EBS and CAPR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTNM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -29.0%. By comparison, EBS (Emergent BioSolutions Inc.) holds a D grade (48/100 RQD, P/E 7.0x, ROIC 8.9%, cap $349.2M) and CAPR (Capricor Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $370.9M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CTNM?
β–Ό

Per CTNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855175), Contineum Therapeutics Inc. (Class A) generated $190.6M in revenue (+33.7% YoY), -$60.0M in net income, and -$55.5M in free cash flow against $276.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.57 (+0.14%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (28/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510028
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (6)Whales (3)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
$19 Bull$8 Base$6 Bear
πŸ“¬ FREE CTNM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CTNM)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
πŸ” WHY CTNM SCORES 28/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
20
Grade E$8.42+0.5% Next Q
Q2 (-2Q)
23
Grade E$8.46+6.3% Next Q
Q3 (-1Q)
25
Grade E$8.99+6.3% Next Q
Current
28
Grade E$9.56-10% Hist 90D Ξ±
Trajectory: E (20) β†’ E (28)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a CTNM Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While CTNM currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.40) and Max Pain ($10.04) forces dealer call-delta covering toward $18.67.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTNMβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCTNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CTNM)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CTNM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTNM)

  • βœ“Walkthrough of CTNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CTNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.44%πŸ“ HORIZONTAL RANGE
2026-11-03O $9.33H $9.56L $9.33C $9.56VOL 458.6K
RES: $18.57SUP: $5.59SMA50: $12.40SMA200: $13.53
$18.55$15.35$12.14$8.93$5.72RES $18.57SUP $5.59$9.562026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CTNM Butterfly Map β†’ + Track CTNM β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +33.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CTNM today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CTNM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTNM)

Health Care Rank #858 of 1015 βš”οΈ EBS vs CTNM Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CTNM vs. EBS, CAPR, SPRY, GALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Contineum Therapeutics Inc. (Class A) (CTNM) ranks #858 by composite RQD confidence (28/100, grade E) and #494 by equity capitalization ($353.3M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with CTNM at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CTNM ACTIVE
Contineum Therapeutics Inc. (Class A)
E 28/100 β€” β€” -29.0% +1.81% $353.3M Benchmark Subject
EBS
Emergent BioSolutions Inc.
D 48/100 7.0x 56.1% 8.9% -5.43% $349.2M /ebs-vs-ctnm β†’
CAPR
Capricor Therapeutics Inc.
E 34/100 β€” β€” -35.0% +13.48% $370.9M /capr-vs-ctnm β†’
SPRY
ARS Pharmaceuticals Inc.
E 20/100 β€” β€” -35.0% -9.76% $336.1M /spry-vs-ctnm β†’
GALT
Galectin Therapeutics Inc.
D- 37/100 β€” β€” -35.0% +0.30% $335.6M /galt-vs-ctnm β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001855175 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Contineum Therapeutics Inc. (Class A) (CTNM) reported GAAP revenue of $190.6M (+33.7% vs. FY2024 revenue of $142.5M , and +281.1% cumulative change since FY2023) , GAAP net income of -$60.0M, operating cash flow of -$55.3M, and free cash flow of -$55.5M (-66.5% YoY). On the balance sheet, CTNM closed FY2025 with $276.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $190.6M -$60.0M -$55.3M -$55.5M $276.6M β€”
FY2024 (FY) 2024-12-31 $142.5M -$42.3M -$32.8M -$33.4M $212.8M β€”
FY2023 (FY) 2023-12-31 $50.0M $22.7M $19.3M $19.3M β€” β€”

3. CTNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Contineum Therapeutics Inc. (Class A) (NASDAQ: CTNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $9.56 (+1.81% 1D, market cap $353.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTNM ranks #858 in composite RQD confidence.

How does CTNM compare to EBS and CAPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTNM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -29.0%. By comparison, EBS (Emergent BioSolutions Inc.) holds a D grade (48/100 RQD, P/E 7.0x, ROIC 8.9%, cap $349.2M) and CAPR (Capricor Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $370.9M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTNM?

Per CTNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855175), Contineum Therapeutics Inc. (Class A) generated $190.6M in revenue (+33.7% YoY), -$60.0M in net income, and -$55.5M in free cash flow against $276.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTNM trading relative to its 50-day, 200-day, and 52-week technical levels?

CTNM last traded at $9.56 (+1.81% on volume of 369,020 shares), positioning the stock -22.90% below its 50-day simple moving average ($12.40) and -29.34% below its 200-day simple moving average ($13.53). Across its 52-week range of $6.72 to $17.78, CTNM sits at the 25.7% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($8.36 to $10.76).

Direct Sub-Reports: CTNM RQD Cockpit CTNM 12M Forecast CTNM Earnings & Move CTNM Dividends & DRIP CTNM Insiders & 13F CTNM Whale Options CTNM Profit Sankey CTNM News & Why
ROARABLE RATING BRIEF β€’ RQD 28/100 (E) βœ“ SEC XBRL & RQD VERIFIED

CTNM β€” Contineum Therapeutics Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Contineum Therapeutics Inc. (Class A) (CTNM) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $9.56 (+1.81% 1D, market capitalization $353.3M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -29.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of -15.82%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Contineum Therapeutics Inc. (Class A) (CTNM) is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Reported revenue is β€” for FY 2025 and FY 2024, versus $50.0M for FY 2023, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Contineum Therapeutics Inc. (Class A) (CTNM) reported $190.6M in annual revenue (up from $142.5M in FY2024, +33.7% YoY) and -$60.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($50.0M revenue, $22.7M net income) through FY2025, CTNM scaled operating cash flow to -$55.3M and free cash flow to -$55.5M, backed by $276.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -15.82% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $6.72 – $17.78 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CTNM carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can CTNM sustain or expand its β€” operating margin and -29.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $190.6M and free cash flow of -$55.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CTNM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CTNM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Contineum Therapeutics Inc. (Class A) (CTNM) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CTNM Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CTNM Bull vs. Bear Conversation Board β€” What's Your Call at $9.56?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTNM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CTNM:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER β€’ Institutional Buy-Side πŸ‚ BULLISH 🎯 Target: $11.74 (+25.0%)
πŸ“Œ Pinned Debate

A cited Bristol Myers Squibb positive Phase 3 result drove a 27% share surge, and a rating upgrade to Buy was reported.

Don't sleep on CTNM's setup in Health Care. A cited Bristol Myers Squibb positive Phase 3 result drove a 27% share surge, and a rating upgrade to Buy was reported.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (28/100) backs up the fundamental quality.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” CTNM's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $7.98 (-15.0%)
Spot @ $9.39

Operating losses widened from -$50.9M in FY 2024 to -$68.1M in FY 2025 while free cash flow stayed negative at -$55.5M.

Sitting on the sidelines or leaning short CTNM above $9.39. Operating losses widened from -$50.9M in FY 2024 to -$68.1M in FY 2025 while free cash flow stayed negative at -$55.5M.. Until Fundamental Cash Engine (6/20) and FCF yield (-15.82%) inflect higher, upside is capped near $17.78.

LIVE TAPE